PURPOSE: This study explores the experiences of individuals in early, middle, and late adolescence dying from cancer. Place of death, medications used at end of life (EOL), and discussions prior to death are examined. METHODS: Data were obtained from a retrospective review of medical charts from 103 adolescents who died of cancer between 2000 and 2005. RESULTS: Adolescents with leukemia/lymphoma were relatively more likely to die in an intensive care unit (p = 0.028) where cause of death was more likely to be treatment-related (p < 0.001), and EOL discussions more likely to occur in the last 7 days of life (p = 0.002). Anxiolytic use was significantly higher during late adolescence (p = 0.037). CONCLUSIONS: Adolescents have unique developmental needs that should be considered at EOL. Timing of EOL discussions occurred very close to death for a significant number of adolescents, allowing very little time to psychologically prepare for death.
PURPOSE: This study explores the experiences of individuals in early, middle, and late adolescence dying from cancer. Place of death, medications used at end of life (EOL), and discussions prior to death are examined. METHODS: Data were obtained from a retrospective review of medical charts from 103 adolescents who died of cancer between 2000 and 2005. RESULTS: Adolescents with leukemia/lymphoma were relatively more likely to die in an intensive care unit (p = 0.028) where cause of death was more likely to be treatment-related (p < 0.001), and EOL discussions more likely to occur in the last 7 days of life (p = 0.002). Anxiolytic use was significantly higher during late adolescence (p = 0.037). CONCLUSIONS: Adolescents have unique developmental needs that should be considered at EOL. Timing of EOL discussions occurred very close to death for a significant number of adolescents, allowing very little time to psychologically prepare for death.
Authors: Janet R Serwint; Lorene E Rutherford; Nancy Hutton; Peter C Rowe; Susan Barker; Graceanne Adamo Journal: Acad Med Date: 2002-04 Impact factor: 6.893
Authors: Richard T Penson; Rosamund A Partridge; Muhammad A Shah; David Giansiracusa; Bruce A Chabner; Thomas J Lynch Journal: Oncologist Date: 2005-02
Authors: Jean-Jacques Georges; Bregje D Onwuteaka-Philipsen; Agnes van der Heide; Gerrit van der Wal; Paul J van der Maas Journal: Support Care Cancer Date: 2004-12-02 Impact factor: 3.603
Authors: Meaghann S Weaver; Katherine E Heinze; Katherine P Kelly; Lori Wiener; Robert L Casey; Cynthia J Bell; Joanne Wolfe; Amy M Garee; Anne Watson; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2015-12 Impact factor: 3.167
Authors: Meaghann S Weaver; Katherine E Heinze; Cynthia J Bell; Lori Wiener; Amy M Garee; Katherine P Kelly; Robert L Casey; Anne Watson; Pamela S Hinds Journal: Palliat Med Date: 2015-04-28 Impact factor: 4.762
Authors: Ursula M Sansom-Daly; Claire E Wakefield; Pandora Patterson; Richard J Cohn; Abby R Rosenberg; Lori Wiener; Joanna E Fardell Journal: J Adolesc Young Adult Oncol Date: 2019-10-29 Impact factor: 2.223